OSI-906
Drug timelines are a Plus or Pro feature.
15 regulatory and trial events tracked for OSI-906, covering 2012-09-11 to 2025-11-18. Get the full timeline:
Most recent: Clinical Trial Update: Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy [Phase 2]